Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 7.538
Filter
1.
Cell Mol Life Sci ; 81(1): 380, 2024 Sep 02.
Article in English | MEDLINE | ID: mdl-39222120

ABSTRACT

The cytokine IFNγ is a principal effector of macrophage activation and immune resistance to mycobacterial infection; however, pathogenic mycobacteria are capable of surviving in IFNγ-activated macrophages by largely unknown mechanisms. In this study, we find that pathogenic mycobacteria, including M. bovis BCG and M. tuberculosis can sense IFNγ to promote their proliferative activity and virulence phenotype. Moreover, interaction with the host intracellular environment increases the susceptibility of mycobacteria to IFNγ through upregulating expression of mmpL10, a mycobacterial IFNγ receptor, thereby facilitating IFNγ-dependent survival and growth of mycobacteria in macrophages. Transmission electron microscopy analysis reveals that IFNγ triggers the secretion of extracellular vesicles, an essential virulence strategy of intracellular mycobacteria, while proteomics identifies numerous pivotal IFNγ-induced effectors required for mycobacterial infection in macrophages. Our study suggests that sensing host IFNγ is a crucial virulence mechanism used by pathogenic mycobacteria to survive and proliferate inside macrophages.


Subject(s)
Interferon-gamma , Macrophages , Mice, Inbred C57BL , Mycobacterium tuberculosis , Interferon-gamma/metabolism , Interferon-gamma/immunology , Macrophages/microbiology , Macrophages/metabolism , Macrophages/immunology , Animals , Mice , Mycobacterium tuberculosis/pathogenicity , Mycobacterium tuberculosis/immunology , Mycobacterium tuberculosis/metabolism , Mycobacterium bovis/immunology , Mycobacterium bovis/metabolism , Humans , Host-Pathogen Interactions/immunology , Virulence , Receptors, Interferon/metabolism , Receptors, Interferon/genetics , Interferon gamma Receptor , Extracellular Vesicles/metabolism , Extracellular Vesicles/immunology , Macrophage Activation , Mycobacterium Infections/microbiology , Mycobacterium Infections/immunology , Mycobacterium Infections/metabolism , Mycobacterium Infections/pathology
2.
Multimedia | Multimedia Resources, MULTIMEDIA-SMS-SP | ID: multimedia-13698

ABSTRACT


Subject(s)
Tuberculosis , Mycobacterium Infections
3.
J Clin Microbiol ; 62(9): e0068324, 2024 Sep 11.
Article in English | MEDLINE | ID: mdl-39136449

ABSTRACT

This study evaluates the growth of mycobacteria in samples from cystic fibrosis (CF) patients and tissue samples using the mycobacteria growth indicator tube (MGIT) incubated at 30°C in comparison to conventional MGIT cultures incubated at 37°C in a BACTEC MGIT 960 device and solid media incubated at 36°C and 30°C. A total of 1,549 samples were analyzed, of which 202 mycobacterial isolates were cultured from 197 positive specimens, including five mixed cultures. The highest detection rate was achieved from MGIT at 30°C, with 84.2% of mycobacterial isolates (170 of 202), which was significantly higher than any other culture condition (P < 0.0001 for any condition). MGIT at 37°C yielded 61.4% (124 of 202) of the recovered isolates, whereas Löwenstein Jensen (LJ) and Stonebrink at 36°C, and LJ and Stonebrink at 30°C retrieved 47.0% (95), 49.5% (100), 50.0% (101), and 53.0% (107) of the isolates, respectively. Of the 53 isolates that were grown exclusively under one culture condition, the highest number of isolates (36) was recovered from MGIT incubated at 30°C. MGIT at 37°C recovered eight of the 53 isolates, whereas LJ incubated at 30°C and Stonebrink incubated at 30°C and 36°C recovered five, three, and one isolate, respectively. No isolates were grown exclusively from LJ incubated at 36°C. In CF patients and tissue samples, MGIT cultivated at 30°C for 8 weeks increases the performance of mycobacterial culture. IMPORTANCE: Our study shows that the addition of mycobacteria growth indicator tube (MGIT) liquid culture incubated at 30°C improves the detection of mycobacteria from CF and tissue samples. MGIT incubated at 30°C recovered significantly more mycobacterial isolates than MGIT incubated at 37°C and significantly more isolates than either Lowenstein Jensen or Stonebrink solid media incubated at either 36°C or 30°C. Of 202 mycobacterial isolates recovered from 1,549 specimens, 170 were recovered from MGIT incubated at 30°C, followed by MGIT incubated at 37°C with 124 isolates and solid media culture conditions that recovered between 95 and 107 mycobacterial isolates. All conventional culture conditions combined without MGIT incubated at 30°C recovered 166 isolates. MGIT incubated at 30°C recovered the highest number of isolates detected exclusively by a single culture condition and recovered mycobacterial isolates of highly relevant mycobacterial species, including Mycobacterium abscessus and Mycobacterium tuberculosis.


Subject(s)
Bacteriological Techniques , Culture Media , Cystic Fibrosis , Temperature , Humans , Culture Media/chemistry , Bacteriological Techniques/methods , Cystic Fibrosis/microbiology , Mycobacterium/growth & development , Mycobacterium/isolation & purification , Mycobacterium Infections/microbiology , Mycobacterium Infections/diagnosis , Child
4.
Balkan Med J ; 41(5): 326-332, 2024 09 06.
Article in English | MEDLINE | ID: mdl-39183693

ABSTRACT

In recent decades, the prevalence of inborn errors of immunity has increased, necessitating the development of more effective treatment and care options for these highly morbid conditions. Due to these "experiments of nature," the complicated nature of the immune system is being revealed. Based on the functional and molecular tests, targeted therapies are now being developed which offer a more effective approach and reduce damage. This study aimed to investigate a key cytokine of the cellular immune response, interferon­gamma (IFN-γ), which is linked to Mendelian susceptibility to Mycobacterial disease, and its potential as a therapeutic option for IFN-γ deficiency.


Subject(s)
Interferon-gamma , Mycobacterium Infections , Humans , Interferon-gamma/analysis , Interferon-gamma/blood , Interferon-gamma/therapeutic use , Genetic Predisposition to Disease
5.
Sci Rep ; 14(1): 19250, 2024 08 20.
Article in English | MEDLINE | ID: mdl-39164329

ABSTRACT

Radiolabelled puromycin analogues will allow the quantification of protein synthesis through nuclear medicine-based imaging. A particularly useful application could be the non-invasive longitudinal visualisation of mycobacterial activity through direct quantification of puromycin binding. This study assesses the value of [68Ga]Ga-DOTA-puromycin in the visualisation of mycobacteria through positron emission tomography combined with magnetic resonance imaging (µPET/MRI). The radiopharmaceutical was produced by previously published and validated methods. [68Ga]Ga-DOTA-Puromycin imaging was performed on severe immunodeficient mice infected with Bacille Calmette-Guérin-derived M. Bovis (BCG). Acute and chronic infection stages were examined by µPET/MRI. A follow-up group of animals acted as controls (animals bearing S. aureus-derived infection and sterile inflammation) to assess tracer selectivity. [68Ga]Ga-DOTA-puromycin-µPET/MRI images revealed the acute, widespread infection within the right upper shoulder and armpit. Also, [68Ga]Ga-DOTA-puromycin signal sensitivity measured after a 12-week period was lower than that of [18F]FDG-PET in the same animals. A suitable correlation between normalised uptake values (NUV) and gold standard histopathological analysis confirms accurate tracer accumulation in viable bacteria. The radiopharmaceutical showed infection selectivity over inflammation but accumulated in both M. Bovis and S. Aureus, lacking pathogen specificity. Overall, [68Ga]Ga-DOTA-puromycin exhibits potential as a tool for non-invasive protein synthesis visualization, albeit without pathogen selectivity.


Subject(s)
Gallium Radioisotopes , Magnetic Resonance Imaging , Mycobacterium bovis , Positron-Emission Tomography , Radiopharmaceuticals , Animals , Magnetic Resonance Imaging/methods , Positron-Emission Tomography/methods , Mice , Radiopharmaceuticals/chemistry , Organometallic Compounds , Heterocyclic Compounds, 1-Ring/chemistry , Mice, SCID , Female , Tuberculosis/diagnostic imaging , Tuberculosis/microbiology , Tuberculosis/metabolism , Mycobacterium Infections/diagnostic imaging , Mycobacterium Infections/microbiology
7.
J Infect Public Health ; 17(8): 102468, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38991411

ABSTRACT

Mendelian susceptibility to mycobacterial disease (MSMD) is caused by approximately 21 genetic defects, including a mutation in Interferon-Gamma Receptor 1 (IFNGR1). IFNGR1 deficiency leads to a loss of cellular responsiveness to type II Interferon (IFN-γ), which plays a significant role in controlling intracellular bacteria. This study explored the response of IFN-ß therapy in a patient with partial IFNGR1 deficiency to treat invasive mycobacterial infection. The biological therapy was used successfully as an adjuvant to anti-mycobacterial medications to treat a 17-year-old girl with partial IFNGR1 deficiency who presented with a recurrent mycobacterial infection that extended to her central nervous system, which resulted in clinical and radiological improvement. This report suggests that activation of type I IFN through Signal Transducers and Activators of Transcription1 (STAT1) could bypass the early IFN-γ signaling defects and activate IFN-γ production. For that reason, IFN-ß might be used as a beneficial adjuvant therapy for managing extensive central nervous system mycobacterial infection, especially in patients with IFNGR1 deficiency.


Subject(s)
Interferon gamma Receptor , Interferon-beta , Mycobacterium Infections , Receptors, Interferon , Humans , Female , Adolescent , Receptors, Interferon/deficiency , Receptors, Interferon/genetics , Interferon-beta/therapeutic use , Mycobacterium Infections/drug therapy , Treatment Outcome , Interferon-gamma/genetics , STAT1 Transcription Factor/genetics , STAT1 Transcription Factor/metabolism
8.
WMJ ; 123(3): 233-237, 2024 Jul.
Article in English | MEDLINE | ID: mdl-39024155

ABSTRACT

INTRODUCTION: Dermatologic manifestations of diseases in solid organ transplant recipients are common due to long-term immunosuppression. CASE PRESENTATION: We present the case of a 63-year-old man with a kidney transplant who exhibited subcutaneous nodules on lower extremities, cytopenia, and asymptomatic pulmonary infiltrate. Through a skin biopsy and 16S ribosomal RNA (rRNA) sequencing, Mycobacterium haemophilum was identified. His clinical course was complicated by empyema, septic arthritis, and recurrence of his skin manifestations, despite ongoing antimicrobial treatment. DISCUSSION: This case emphasizes the challenges and potential complications associated with M haemophilum infections in solid organ transplant recipients receiving long-term immunosuppressive therapy. It highlights the importance of employing advanced diagnostic techniques when evaluating dermatologic manifestations in these patients. The patient's complex clinical course also underscores the difficulties involved in effectively addressing and managing complications that may arise even after initiating therapy.


Subject(s)
Kidney Transplantation , Mycobacterium haemophilum , Humans , Kidney Transplantation/adverse effects , Male , Middle Aged , Mycobacterium haemophilum/isolation & purification , Mycobacterium Infections/diagnosis , Mycobacterium Infections/microbiology , Mycobacterium Infections/drug therapy , Immunocompromised Host
9.
Microbiol Spectr ; 12(8): e0006224, 2024 Aug 06.
Article in English | MEDLINE | ID: mdl-38912807

ABSTRACT

Programmed cell death protein 4 (PDCD4) is instrumental in regulating a range of cellular processes such as translation, apoptosis, signal transduction, and inflammatory responses. There is a notable inverse correlation between PDCD4 and the mammalian target of rapamycin (mTOR) pathway, which is integral to cellular growth control. Activation of mTOR is associated with the degradation of PDCD4. Although the role of PDCD4 is well established in oncogenesis and immune response regulation, its function in mycobacterial infections and its interplay with the mTOR pathway necessitate further elucidation. This study investigates the modulation of PDCD4 expression in the context of mycobacterial infections, revealing a consistent pattern of downregulation across diverse mycobacterial species. This observation underscores the potential utility of PDCD4 as a biomarker for assessing mTOR pathway activation during such infections. Building on this finding, we employed a novel approach using PDCD4-based mTOR (Tor)-signal-indicator (TOSI) reporter cells for the high-throughput screening of FDA-approved drugs, focusing on mTOR inhibitors. This methodology facilitated the identification of several agents, inclusive of known mTOR inhibitors, which upregulated PDCD4 expression and concurrently exhibited efficacy in impeding mycobacterial proliferation within macrophages. These results not only reinforce the significance of PDCD4 as a pivotal marker in the understanding of infectious diseases, particularly mycobacterial infections, but also illuminate its potential in the identification of mTOR inhibitors, thereby contributing to the advancement of therapeutic strategies. IMPORTANCE: This study emphasizes the critical role of the mammalian target of rapamycin (mTOR) pathway in macrophage responses to mycobacterial infections, elucidating how mycobacteria activate mTOR, resulting in PDCD4 degradation. The utilization of the (Tor)-signal-indicator (TOSI) vector for real-time monitoring of mTOR activity represents a significant advancement in understanding mTOR regulation during mycobacterial infection. These findings deepen our comprehension of mycobacteria's innate immune mechanisms and introduce PDCD4 as a novel marker for mTOR activity in infectious diseases. Importantly, this research laid the groundwork for high-throughput screening of mTOR inhibitors using FDA-approved drugs, offering the potential for repurposing treatments against mycobacterial infections. The identification of drugs that inhibit mTOR activation opens new avenues for host-directed therapies, marking a significant step forward in combating tuberculosis and other mycobacterial diseases.


Subject(s)
Apoptosis Regulatory Proteins , Biomarkers , Mycobacterium Infections , RNA-Binding Proteins , Signal Transduction , TOR Serine-Threonine Kinases , TOR Serine-Threonine Kinases/metabolism , Humans , Apoptosis Regulatory Proteins/metabolism , Apoptosis Regulatory Proteins/genetics , RNA-Binding Proteins/metabolism , RNA-Binding Proteins/genetics , Mycobacterium Infections/microbiology , Mycobacterium Infections/drug therapy , Mycobacterium Infections/metabolism , Mycobacterium Infections/immunology , Biomarkers/metabolism , Macrophages/microbiology , Macrophages/immunology , Macrophages/metabolism , Animals , Mice , Mycobacterium/genetics
11.
Microbes Environ ; 39(2)2024.
Article in English | MEDLINE | ID: mdl-38897967

ABSTRACT

To investigate mycobacterial cases of farmed yellowtail fish in coastal areas of western Japan (Kagoshima, Kyushu), where aquaculture fisheries are active, Mycobacterium pseudoshottsii, the causative agent, was isolated from six neighboring fishing ports in 2012 and 2013. A phylogenetic ana-lysis revealed that the strains isolated from one fishing port were closely related to those isolated from other regions of Japan, suggesting the nationwide spread of a single strain. However, strains from Japan were phylogenetically distinct from those from the Mediterranean and the United States; therefore, worldwide transmission was not observed based on the limited data obtained on the strains exami-ned in this study. The present results demonstrate that a bacterial genomic ana-lysis of infected cases, a mole-cular epidemiology strategy for public health, provides useful data for estimating the prevalence and transmission pathways of M. pseudoshottsii in farmed fish. A bacterial genome ana-lysis of strains, such as that performed herein, may play an important role in monitoring the prevalence of this pathogen in fish farms and possible epidemics in the future as a result of international traffic, logistics, and trade in fisheries.


Subject(s)
Aquaculture , Fish Diseases , Genome, Bacterial , Mycobacterium Infections , Phylogeny , Japan/epidemiology , Animals , Fish Diseases/microbiology , Fish Diseases/epidemiology , Mycobacterium Infections/veterinary , Mycobacterium Infections/microbiology , Mycobacterium Infections/epidemiology , Genome, Bacterial/genetics , Mycobacterium/genetics , Mycobacterium/classification , Mycobacterium/isolation & purification , Fishes/microbiology , Fisheries , Genomics , Molecular Epidemiology , Prevalence
12.
Drug Discov Today ; 29(7): 104049, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38830505

ABSTRACT

Tuberculosis (TB) is a significant global health threat, and cases of infection with non-tuberculous mycobacteria (NTM) causing lung disease (NTM-LD) are rising. Bacteriophages and their gene products have garnered interest as potential therapeutic options for bacterial infections. Here, we have compiled information on bacteriophages and their products that can kill Mycobacterium tuberculosis or NTM. We summarize the mechanisms whereby viable phages can access macrophage-resident bacteria and not elicit immune responses, review methodologies of pharmaceutical product development containing mycobacteriophages and their gene products, mainly lysins, in the context of drug regulatory requirements and we discuss industrially relevant methods for producing pharmaceutical products comprising mycobacteriophages, emphasizing delivery of mycobacteriophages to the lungs. We conclude with an outline of some recent case studies on mycobacteriophage therapy.


Subject(s)
Mycobacteriophages , Humans , Animals , Tuberculosis/drug therapy , Mycobacterium tuberculosis , Phage Therapy/methods , Mycobacterium Infections, Nontuberculous/drug therapy , Mycobacterium Infections, Nontuberculous/therapy , Mycobacterium Infections/therapy , Mycobacterium Infections/drug therapy
14.
J Vet Diagn Invest ; 36(4): 569-572, 2024 Jul.
Article in English | MEDLINE | ID: mdl-38653781

ABSTRACT

A 23-y-old gelding was presented to a veterinary teaching hospital with a history of chronic, refractory diarrhea. Clinically, the horse was in poor body condition, with a thickened and corrugated large intestine identified by transcutaneous abdominal ultrasonography. At postmortem examination following euthanasia, the large colon and cecum had segmental thickening of the intestinal wall with innumerable mucosal ulcers and prominent polypoid mucosal masses. Many mesenteric and hepatic lymph nodes were enlarged. Histology revealed granulomatous and ulcerative typhlocolitis and granulomatous lymphadenitis with myriad acid-fast, variably gram-positive, intrahistiocytic bacilli that stained by immunohistochemistry for mycobacteria. Molecular testing by PCR and sequencing identified the causative agent as Mycobacterium genavense, which is an unusual presentation of infection in a horse.


Subject(s)
Horse Diseases , Mycobacterium , Animals , Horses , Horse Diseases/microbiology , Horse Diseases/pathology , Horse Diseases/diagnosis , Mycobacterium/isolation & purification , Mycobacterium/genetics , Male , Mycobacterium Infections/veterinary , Mycobacterium Infections/microbiology , Mycobacterium Infections/pathology , Mycobacterium Infections/diagnosis , Typhlitis/veterinary , Typhlitis/pathology , Typhlitis/microbiology , Typhlitis/diagnosis , Colitis/veterinary , Colitis/microbiology , Colitis/pathology , Fatal Outcome
15.
J Thorac Imaging ; 39(5): 304-311, 2024 Sep 01.
Article in English | MEDLINE | ID: mdl-38662632

ABSTRACT

PURPOSE: The objective of this study is to identify and detail the radiologic manifestations of surgical site and disseminated Mycobacterium chimaera ( MC) infection. The aim is to facilitate early identification and diagnosis of MC, considering its indolent nature and the challenges involved in clinically and pathologically establishing the diagnosis. PATIENTS AND METHODS: This was a retrospective cohort study reviewing computed tomography (CT), positron emission tomography (PET)/CT, and magnetic resonance imaging examinations in patients over the age of 18 years with a history of open heart surgery and a clinical or pathologic diagnosis of MC. Two radiology residents, a fellowship-trained nuclear medicine radiologist, and a fellowship-trained cardiothoracic radiologist performed consensus reads to determine the imaging findings seen in MC infection. RESULTS: Twenty-five patients were included. Localized, surgical site infection was more common than disseminated disease. Typical CT findings included peristernal soft tissue thickening, sinus tracts often extending to the cutaneous surface, slowly enlarging fluid collections, and sternal osteolysis. PET/CT findings demonstrated hypermetabolic activity in nearly all patients localized to sites of infection. Imaging findings for disseminated infection included hepatosplenomegaly, lymphadenopathy, involvement of the central nervous system, discitis/osteomyelitis, and distant abscesses. CONCLUSIONS: Imaging plays a vital role in suggesting possible surgical sites and disseminated MC infection acquired from open heart surgery. Radiologists must keep a high index of suspicion given the indolent nature and subtle imaging change over time. PET/CT is most useful in diagnosis and helps in differentiating between a sterile postoperative fluid collection or scarring and active MC infection and helps provide a target for debridement.


Subject(s)
Cardiac Surgical Procedures , Magnetic Resonance Imaging , Tomography, X-Ray Computed , Humans , Retrospective Studies , Male , Female , Middle Aged , Aged , Tomography, X-Ray Computed/methods , Cardiac Surgical Procedures/methods , Magnetic Resonance Imaging/methods , Positron Emission Tomography Computed Tomography/methods , Adult , Mycobacterium , Mycobacterium Infections, Nontuberculous/diagnostic imaging , Surgical Wound Infection/diagnostic imaging , Cohort Studies , Mycobacterium Infections/diagnostic imaging , Aged, 80 and over
16.
Zhonghua Jie He He Hu Xi Za Zhi ; 47(4): 360-362, 2024 Apr 12.
Article in Chinese | MEDLINE | ID: mdl-38599813

ABSTRACT

Here, we reported the diagnosis and treatment of a case of HIV infected person complicated by an extremely rare infection with Mycobacterium celatum. Due to the similarity of homologous sequence regions between Mycobacterium celatum and Mycobacterium tuberculosis complex, the identification of conventional Mycobacterium species was incorrect, which was corrected after first-generation 16S rRNA sequencing. This report aimed to improve the clinical understanding of Mycobacterium celatum infection and the level of differential diagnosis between non-tuberculous mycobacterial disease and tuberculosis.


Subject(s)
HIV Infections , Mycobacterium Infections , Mycobacterium , Humans , RNA, Ribosomal, 16S/genetics , Mycobacterium/genetics , Mycobacterium Infections/diagnosis , Mycobacterium Infections/microbiology , Nontuberculous Mycobacteria/genetics , HIV Infections/complications
17.
Int J Mol Sci ; 25(6)2024 Mar 09.
Article in English | MEDLINE | ID: mdl-38542119

ABSTRACT

Mycobacterium tuberculosis (Mtb) employs various strategies to manipulate the host's cellular machinery, overriding critical molecular mechanisms such as phagosome-lysosome fusion, which are crucial for its destruction. The Protein Kinase C (PKC) signaling pathways play a key role in regulating phagocytosis. Recent research in Interferon-activated macrophages has unveiled that PKC phosphorylates Coronin-1, leading to a shift from phagocytosis to micropinocytosis, ultimately resulting in Mtb destruction. Therefore, this study aims to identify additional PKC targets that may facilitate Mycobacterium bovis (M. bovis) infection in macrophages. Protein extracts were obtained from THP-1 cells, both unstimulated and mycobacterial-stimulated, in the presence or absence of a general PKC inhibitor. We conducted an enrichment of phosphorylated peptides, followed by their identification through mass spectrometry (LC-MS/MS). Our analysis revealed 736 phosphorylated proteins, among which 153 exhibited alterations in their phosphorylation profiles in response to infection in a PKC-dependent manner. Among these 153 proteins, 55 are involved in various cellular processes, including endocytosis, vesicular traffic, autophagy, and programmed cell death. Importantly, our findings suggest that PKC may negatively regulate autophagy by phosphorylating proteins within the mTORC1 pathway (mTOR2/PKC/Raf-1/Tsc2/Raptor/Sequestosome-1) in response to M. bovis BCG infection, thereby promoting macrophage infection.


Subject(s)
Mycobacterium Infections , Mycobacterium bovis , Mycobacterium tuberculosis , Humans , Mycobacterium bovis/physiology , Chromatography, Liquid , Tandem Mass Spectrometry , Macrophages/metabolism , Autophagy , Mycobacterium Infections/metabolism , Protein Kinase C/metabolism
18.
Pediatr Allergy Immunol Pulmonol ; 37(1): 33-36, 2024 Mar.
Article in English | MEDLINE | ID: mdl-38484269

ABSTRACT

Background: Autosomal recessive interleukin (IL)-12p40 deficiency is a genetic etiology of Mendelian susceptibility to mycobacterial disease (MSMD). It has been described in ∼50 patients, usually with onset at childhood with Bacille Calmette-Guérin (BCG) and Salmonella infections. Case Presentation: A male patient born to consanguineous parents was diagnosed with presumed lymph node MSMD at the age of 13 years after ocular symptoms. A positive history of inborn error of immunity was present: BCG reaction, skin abscess, and recurrent oral candidiasis. Abnormal measurements of cytokine levels, IL-12p40 and interferon-gamma (IFN-γ), lead to the diagnosis of MSMD. Genetic analysis showed a mutation in exon 7 of the IL12B gene. Currently, the patient is alive under prophylactic antibiotics. Conclusion: We report a rare case of IL-12p40 deficiency in a Latin American patient. Medical history was crucial for immune defect suspicion, as confirmed by precision diagnostic medicine tools.


Subject(s)
Interleukin-12 Subunit p40 , Mycobacterium Infections , Humans , Male , Child , Interleukin-12 Subunit p40/genetics , Brazil , Mycobacterium Infections/diagnosis , Mycobacterium Infections/genetics , Mutation , Lymph Nodes
20.
Pediatr Infect Dis J ; 43(6): 543-549, 2024 Jun 01.
Article in English | MEDLINE | ID: mdl-38377462

ABSTRACT

BACKGROUND: The incidence of pediatric inflammatory bowel disease is increasing. tumor necrosis factor alpha inhibitors medicines improved the prognosis of affected subjects. Nonetheless, a proportion of patients do not respond or lose response to treatment. Newer biologics, like ustekinumab, have been approved for adults. The pediatric off-label use of these drugs is increasing, despite limited safety evidence. We report a case of disseminated mycobacterial infection (MI) presenting with reactive polyarthritis (Poncet's disease, PD) in a girl with Crohn's disease receiving various immunosuppressants, including ustekinumab. CASE REPORT: A 12-year-old girl with Crohn's disease was admitted for acute-onset migratory polyarthritis of large and small joints and opioid-resistant pain. She had recently received adalimumab and methotrexate and was currently under treatment with ustekinumab. She was vaccinated with Bacillus Calmette-Guérin and screened for tuberculosis before starting immunosuppressants. Interferon-gamma release assay, Mantoux test and chest computed tomography scan were negative. Disseminated MI with PD was diagnosed following positive cultures for Mycobacterium tuberculosis complex in blood and intestinal biopsies (with negative in synovial fluid and gastric aspirate). Whole-exome sequencing did not identify any genetic susceptibility to MI. Antituberculosis treatment eradicated MI. CONCLUSIONS: Children with inflammatory bowel disease receiving combination immunosuppressive treatments including tumor necrosis factor alpha inhibitors and anti-IL-12/23 agents are at higher risk for MI. Disseminated MI should be considered and ruled out in these patients when presenting with pulmonary, extrapulmonary or unusual clinical manifestations, like PD. The collection of multiple specimens (including intestinal biopsies) for mycobacterial culture is recommended when mycobacterial disease is suspected.


Subject(s)
Crohn Disease , Immunosuppressive Agents , Ustekinumab , Humans , Female , Crohn Disease/drug therapy , Crohn Disease/complications , Child , Ustekinumab/therapeutic use , Ustekinumab/adverse effects , Immunosuppressive Agents/therapeutic use , Immunosuppressive Agents/adverse effects , Arthritis, Reactive/drug therapy , Arthritis, Reactive/microbiology , Mycobacterium Infections/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL